Table 4.
Management characteristics of patients with atrial fibrillation.
| Study | DCCV N (%) | Pharmacologic CV N (%) | AAD N (%) | Beta-blocker N (%) | CCB N (%) | Digoxin N (%) | Rhythm control N (%) | Rate control N (%) | OAT N (%) | ASA N (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Canadian Registry of AF [14] | 155 (17) | 611 (68) | 315 (35) | 120 (31) | 142 (16) | 385 (43) | – | – | 284 (32) | – |
| Stockholm Cohort Study of AF [15] | – | – | – | 50 (2) | – | – | – | – | 1130 (40) | 1158 (41) |
| Pappone et al. [16] | 31 (29) | – | 56 (53) | – | – | – | –– | – | – | – |
| Euro Heart Survey [17] | 900 (17) | 1128 (21) | 2089 (39) | 2236 (42) | 463(9) | 1369 (26) | – | – | 3271 (61) | 1490 (28) |
| AFIB Cameroon [18] | 4 (2) | – | – | 20 (12) | 15 (9) | 108 (63) | 28 (16) | 144 (84) | 57 (33) | 105 (61) |
| RecordAF [19] | – | – | 616 (11) | 4035 (72) | 841 (15) | 1905 (34) | 3076 (55) | 2528 (45) | 2914 (52) | 2353 (42) |
| Belgrade Atrial Fibrillation Study [20] | – | – | – | – | – | – | – | – | – | – |
| AFFECTS [21] | – | – | 412 (28) | 632 (43) | 345 (24) | 323 (22) | 942 (65) | 519 (35) | 930 (64) | 464 (32) |
AAD - antiarrhythmic drug, ASA - aspirin, CCB - calcium channel blocker, DCCV - direct current cardioversion, OAT - oral anticoagulation therapy.